Compare ImmunityBio Inc. Common Stock (IBRX) vs iShares Core MSCI Emerging Markets ETF (IEMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs iShares Core MSCI Emerging Markets ETF — how do they compare? ImmunityBio Inc. Common Stock trades at $10.53 (market cap $10.51B), while iShares Core MSCI Emerging Markets ETF trades at $81.35 (market cap $162.00B). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 15.4× ImmunityBio Inc. Common Stock's market cap, and ImmunityBio Inc. Common Stock is trading nearer its 52-week high, iShares Core MSCI Emerging Markets ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 1 Days and iShares Core MSCI Emerging Markets ETF for 57 Days on average.
| IBRX | IEMG | |
|---|---|---|
Market Cap | $10.51B | $162.00B |
Volume | 10,445,785 | 13,446,151 |
Sector | Health | Broad Market / Factor |
52-Week High | $11.55 | $86.00 |
52-Week Low | $1.98 | $64.22 |
Typical Hold Time | 1 Days | 57 Days |
Enterprise Value | $10.97B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
IEMG trades at $81.40, down 0.78% with bearish technical signals from moving averages while oscillators remain neutral. The emerging markets ETF has demonstrated strong performance with 35% returns over the past year according to recent analysis, though faces competition from lower-cost alternatives. Recent news highlights emerging markets attracting record capital flows as investors diversify beyond US mega-cap technology stocks.
The outlook remains cautiously optimistic given emerging markets' recent outperformance and dollar weakness, though higher expense ratios compared to competitors and concentration in technology sectors present risks. Technical indicators suggest near-term pressure with support at $79-80 levels, while fundamental strength in emerging market growth supports longer-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →
